Announced Sat, 18 Jul · 16:49 IST
Board approves Q1 results, ESOP allotment, subsidiary transfer
Capital Market Events View source PDF
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹530.05
prior close
—
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-3.4-6.2-7.2-7.6-1.5—————
Up moveDown movePending
AI summary
Rossari Biotech posted Q1 FY27 consolidated revenue of Rs. 6,972 million (up 28% YoY) and PAT of Rs. 351 million. Standalone revenue rose 32% to Rs. 4,823 million with PAT of Rs. 343 million. Board allotted 2,500 shares under ESOP 2019 at Rs. 425 each and granted 4,000 new options at Rs. 531. Also approved transfer of Saudi arm Rossari International to its Singapore subsidiary for about Rs. 24 crores as internal restructuring.
Likely market impact
Minor dilution from ESOP allotment is negligible. Subsidiary transfer is internal restructuring with no material financial impact. Strong YoY revenue and profit growth.